Table of Contents How to use these guidelines Abbreviations MODULES 1. What’s new the 2023 guidelines update? 2. Nucleoside/nucleotide reverse transcriptase inhibitor class of antiretroviral drugs 3. Integrase strand transfer inhibitor class of antiretroviral drugs 4. Non-nucleoside reverse transcriptase inhibitor class of antiretroviral drugs 5. Protease inhibitor class of antiretroviral drugs 6. Initiation and timing of antiretroviral therapy 7. Baseline investigations 8. Viral load 9. CD4⁺ cell count 10. Resistance and genotyping 11. Initial antiretroviral therapy regimens for the previously untreated patient 12. Management of patients currently receiving first-line therapy 13. Management of patients starting or currently receiving second-line therapy 14. Third-line antiretroviral therapy 15. Laboratory monitoring of the efficacy and safety of antiretroviral therapy 16. Patients who return after stopping antiretroviral therapy 17. Drug-drug interactions 18. Tuberculosis 19. Pregnancy and breastfeeding 20. Liver disease 21. Renal disease 22. Psychiatric disease 23. Malaria 24. Antiretroviral drug-induced liver injury 25. Dyslipidaemia 26. Immune reconstitution inflammatory syndrome 27. Opportunistic infection prophylaxis 28. Adherence
References